AOD-9604
Human Growth Hormone C-Terminal Fragment (Tyr-hGH177-191)
Pre-Clinical Overview
AOD-9604 is a synthetic hexadecapeptide analog representing the lipolytic C-terminal domain of human growth hormone (hGH 177-191) with an added tyrosine residue. Investigated in UK metabolic and adipose tissue laboratories for beta-3 adrenergic receptor signaling without diabetogenic IGF-1 elevation.
Verified UK Suppliers for AOD-9604
| Supplier | Assay Purity | Reagent Format | Dispatch Location | Notes | Access |
|---|---|---|---|---|---|
| PharmaGrade Store | ≥99.1% (HPLC) | vial | United Kingdom (Royal Mail 24) | High-purity lyophilized 5mg vials tested for intact disulfide bridge conformation. | |
| Direct Peptides | ≥99.0% (HPLC) | vial | UK Hub & Europe | Research grade lyophilized peptide vials with automated mass spectrometry confirmation. | |
| Direct Sarms | ≥98.5% (HPLC) | vial | United Kingdom Express | Analytical reference standard vials tested for adipocyte lipolysis assays. | |
| Peptide Works | ≥98.7% (HPLC) | vial | Manchester UK Hub | Northern UK laboratory dispatched lyophilized reagent vials with sequence COA. | |
| PharmaLab Global | ≥99.3% (HPLC) | vial | London UK Hub | Triple-stage assayed vials and pre-calibrated laboratory multi-dose pen formats. |
Molecular Signaling Pathways
- 1Selectively activates lipolysis via beta-3 adrenergic receptor pathways in isolated adipocyte assays.
- 2Stimulates hormone-sensitive lipase (HSL) phosphorylation, accelerating triacylglycerol breakdown.
- 3Inhibits lipogenesis by suppressing acetyl-CoA carboxylase activity in adipose tissue explants.
- 4Does not bind the human growth hormone receptor, avoiding insulin antagonism and mitogenic stimulation.
Laboratory Evaluation Guidelines
Contains an internal disulfide bond between Cys7 and Cys14 required for biological conformation. Careful handling is necessary to avoid reduction of this disulfide bridge during reconstitution.
Receptor Affinity, SPPS Synthesis & Pharmacokinetics
Standardized chemical parameters, solid-phase synthesis criteria, and quantitative receptor affinity benchmarks for AOD-9604.
- Hormone-sensitive lipase (HSL) enzymatic stimulation
- Inhibition of acetyl-CoA carboxylase and lipogenesis
- Adipose fatty acid beta-oxidation induction
Documented Biochemical Endpoints & Statistical Significance
| Study Design | Cohort (n) | Measured Biological Endpoint | Statistical Significance | NCBI Citation |
|---|---|---|---|---|
| In Vitro Assay | n = 32 isolated adipocyte culture models | Glycerol release (lipolysis) & lipid droplet reduction | p < 0.001 vs vehicle | PMID 11717208 |
| Preclinical In Vivo | n = 60 metabolic rodent models | Triglyceride reduction without glycemic or IGF-1 perturbation | p < 0.01 | PMID 25236178 |
Indexed Scientific Literature
Curated Scientific Q&A for AOD-9604
Authoritative pre-clinical, analytical, and statutory handling guidelines for laboratory researchers.
AOD-9604 (Human Growth Hormone C-Terminal Fragment (Tyr-hGH177-191)) is indexed in the CAS Registry under #221231-10-3. Its empirical molecular formula is C78H123N23O23S2 with a monoisotopic molecular weight of 1815.12 g/mol. It is cataloged under the Metabolic & Incretin Signaling research classification.
More Reagents in Metabolic & Incretin Signaling
Tirzepatide
Dual GIP and GLP-1 Receptor Co-Agonist 39-AA Synthetic Peptide
Tirzepatide is a synthetic 39-amino-acid unimolecular dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist conjugated to a C20 fatty diacid moiety. Studied extensively in UK biochemical and pharmaceutical research for receptor affinity dynamics.
Semaglutide
Acylated GLP-1 Analogue (31-AA Chain with C18 Diacid Spacer)
Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonist modified at position 8 with alpha-aminoisobutyric acid (Aib) and acylated at Lys26 with a C18 fatty diacid chain. Studied in UK endocrinology and metabolic research as a classical mono-incretin reference standard.